Is Hormone Replacement Therapy Safe for Women Over 60?

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published August 8, 2025 • Updated May 3, 2026

If you are over 60 and asking whether hormone replacement therapy is safe, I want to separate fear from medicine. The answer is not a blanket yes. It is not a blanket no. The answer depends on whether you are starting for the first time, continuing a treatment that has worked, using local vaginal estrogen, or treating a clear symptom with the wrong route or dose.

I see too many women come in after being told, “You are too old for hormones,” with no discussion of symptoms, sleep, sexual pain, urinary issues, bone risk, migraine history, clot risk, uterus status, or cardiovascular health. I also see the other extreme: women being promised that hormones after 60 will reverse aging, prevent dementia, and fix every problem. Both extremes are poor medicine.

For me, the clinical question is narrower and more useful: what symptom are we treating, what formulation are we considering, what are her contraindications, and does the expected benefit justify the risk in this specific woman?

The Short Answer: Safety Depends on Timing

Timing matters because the body at 52 is not the same as the body at 67. A woman who starts hormone therapy during perimenopause or early menopause is usually being treated closer to the estrogen decline that triggered her symptoms. A woman starting systemic estrogen for the first time at 66 may have a different vascular baseline, different plaque burden, different clot risk, and different medication list.

The NAMS 2022 hormone therapy position statement is useful because it gives nuance. For women younger than 60 or within 10 years of menopause, the benefit-risk profile is generally favorable for bothersome hot flashes, night sweats, and prevention of bone loss in appropriate candidates. For women who start more than 10 years from menopause or after age 60, the benefit-risk profile is less favorable because absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia rise with age.

That does not mean every woman over 60 must stop. It means the conversation becomes more individualized. Continuing a stable, effective, low-dose plan after periodic review is different from initiating high-dose oral estrogen in a woman with untreated hypertension and a prior clot. Age is a risk variable, not the whole diagnosis.

Starting HRT After 60 Is Different From Continuing It

This is the distinction I want women to remember. Starting systemic hormone therapy for the first time after 60, especially more than 10 years after the final period, deserves more caution. I review cardiovascular risk, stroke history, clot history, breast cancer history, uterine status, liver disease, migraine pattern, smoking status, blood pressure, lipids, A1c, weight pattern, and the symptom being treated.

Continuing hormone therapy after 60 can be reasonable for selected women. NAMS states that hormone therapy does not have to be routinely discontinued at 60 or 65. Instead, we reassess. Is she still having significant vasomotor symptoms? Is sleep falling apart when she tapers? Is she using it for bone protection because other options are not appropriate? Is the dose still the lowest effective dose? Would a transdermal route reduce risk? Does she still need progesterone because the uterus is present?

I do not automatically pull a therapy that is helping simply because a birthday arrived. I also do not renew hormones year after year without asking whether the plan still fits. Over 60, good care means periodic review, not autopilot.

If your symptoms restarted after stopping, that is clinically relevant. If you are on hormones because nobody ever revisited them, that is also clinically relevant. The next step is not panic. The next step is a risk-based review through a qualified clinician who understands hormone replacement therapy for women and the realities of menopause after 60.

Route, Dose, and Uterus Status Change the Risk

When people say “HRT,” they often collapse very different treatments into one category. A pill, patch, gel, spray, vaginal cream, vaginal tablet, ring, compounded pellet, and FDA-approved progesterone capsule are not the same medical exposure.

Route matters. Oral estrogen goes through the liver first, which can influence clotting factors and triglycerides. Transdermal estradiol, delivered through the skin as a patch, gel, or spray, avoids that first-pass liver effect and is often considered when clot or metabolic risk is a concern. That does not make it risk-free. It makes the route part of the decision.

Dose matters. I want the lowest effective dose for the treatment goal, not the lowest dose that leaves a woman miserable and not the highest dose because someone sold hormones as youth restoration. The dose that controls severe hot flashes may not be the dose needed for vaginal dryness. The dose appropriate at 51 may not be the dose I would keep at 64.

Uterus status matters. If you still have a uterus and use systemic estrogen, you usually need endometrial protection with progesterone or another appropriate progestogen. Estrogen without protection can stimulate the uterine lining. If you had a hysterectomy, progesterone may not be needed for uterine protection, though individual situations differ. This is why your surgical history belongs in every HRT conversation.

Who Should Avoid Systemic Hormone Therapy

Some women are not good candidates for systemic hormone therapy, and this is where direct counseling matters. I am cautious or usually avoid systemic hormones in women with unexplained vaginal bleeding, active or prior estrogen-sensitive cancer, prior stroke, heart attack, pulmonary embolism, deep vein thrombosis, known high-risk clotting disorders, active liver disease, or uncontrolled cardiovascular risk.

The American College of Obstetricians and Gynecologists describes systemic estrogen as the most effective treatment for hot flashes and night sweats, but it also emphasizes individualized risk. ACOG recommends FDA-approved hormone therapy over compounded hormone therapy because dose, purity, and safety monitoring matter.

I am especially careful with pellet therapy in women over 60. Pellets can create prolonged exposure that is harder to adjust quickly if side effects or risk concerns appear. If a woman has breast tenderness, bleeding, mood changes, acne, hair changes, or a supraphysiologic lab pattern, I want the ability to lower or stop treatment without waiting months for a pellet to wear down.

Contraindications do not mean suffering is the only option. Nonhormonal medications, sleep treatment, vaginal moisturizers, pelvic floor therapy, urinary symptom evaluation, bone medications, and metabolic care may all be part of the plan. The point is to match the treatment to the risk, not force every woman into or out of hormones.

Vaginal Estrogen Is a Different Conversation

Low-dose vaginal estrogen is not the same as systemic HRT. It is used for genitourinary syndrome of menopause: vaginal dryness, burning, pain with sex, recurrent urinary symptoms, and tissue fragility. The absorption is generally much lower than systemic therapy, and many women who are not candidates for systemic estrogen may still be able to discuss local therapy with their clinician.

This matters because women over 60 are often told they are “too old for estrogen” when the actual problem is vaginal and urinary tissue estrogen deficiency. Pain with intimacy, recurrent UTIs, burning, tearing, and dryness are not character flaws. They are common postmenopausal tissue changes. Gaya addresses these symptoms through menopause care, menopause evaluation, and options such as vaginal rejuvenation when appropriate.

The FDA's menopause hormone therapy labeling has also changed. In February 2026, the FDA approved labeling changes for several menopausal hormone therapy products, including removal of certain boxed-warning language related to cardiovascular disease, breast cancer, and probable dementia from those products. I do not interpret that as permission to prescribe casually. I interpret it as a reminder that old fear-based counseling should be replaced by current, individualized risk discussion.

How I Evaluate a Woman Over 60 at Gaya

My first question is not, “Do you want hormones?” My first question is, “What are we trying to treat?” Hot flashes, night sweats, insomnia, mood changes, brain fog, vaginal dryness, urinary symptoms, joint pain, bone loss, libido changes, and weight gain can overlap, but they do not always have the same treatment.

Then I map timing. When was your final period? Did you have early menopause, surgical menopause, chemotherapy, or ovarian removal? Have you used hormones before? Did you stop because symptoms resolved, because someone scared you, or because insurance changed? A woman ten years past menopause with no uterus and severe night sweats is not the same clinical scenario as a woman twenty years past menopause with prior stroke and no current vasomotor symptoms.

I review route and dose, including compounded products. I ask about breast imaging, abnormal bleeding, migraine aura, clot history, family history, tobacco, blood pressure, cholesterol, diabetes risk, liver disease, and current medications. I also ask about goals. If the goal is fewer hot flashes and better sleep, we can measure whether treatment is working. If the goal is “anti-aging,” I slow the conversation down because that claim often hides risk.

The Mayo Clinic notes that starting hormone therapy at 60 or older, or more than 10 years from menopause, increases the risk of serious complications. That statement belongs in the room. So does the reality that untreated symptoms can damage sleep, relationships, function, and quality of life. Good care holds both truths.

What I Tell My Patients Over 60

I tell them that hormones are not a moral issue. Taking HRT does not mean you are weak, vain, or reckless. Declining HRT does not mean you are uninformed. The question is whether the treatment fits your biology, your symptoms, and your risk profile today.

If you are over 60 and already on HRT, do not stop abruptly without a plan unless your clinician tells you there is an urgent safety reason. Schedule a review. Ask whether your dose, route, and progesterone plan still make sense. Ask whether transdermal estradiol is preferable for you. Ask whether your vaginal symptoms need local therapy instead of systemic escalation.

If you are over 60 and want to start for the first time, expect a more careful evaluation. That is not age discrimination. That is medicine. We may still treat. We may choose nonhormonal options first. We may treat vaginal symptoms locally. We may prioritize blood pressure, lipids, insulin resistance, sleep apnea, or bone health before systemic estrogen.

Inside Hormonal Agency™, I build this decision around symptoms, history, medication exposure, labs, risk, and follow-up. We also discuss related midlife drivers such as perimenopause, metabolic changes, stubborn weight gain, and long-term health through Her Longevity. Hormone care should be adult medicine, not a sales script.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in hormone optimization, menopause hormone therapy, and longevity medicine for women in midlife and beyond.

You have not failed. Your plan did.